Frazier Life Sciences Management’s HilleVax HLVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-10,617,062
| Closed | -$21.1M | – | 51 |
|
|
2025
Q2 | $21.1M | Hold |
10,617,062
| – | – | 0.84% | 25 |
|
|
2025
Q1 | $15.4M | Hold |
10,617,062
| – | – | 0.7% | 29 |
|
|
2024
Q4 | $22M | Hold |
10,617,062
| – | – | 0.91% | 24 |
|
|
2024
Q3 | $18.7M | Hold |
10,617,062
| – | – | 0.75% | 29 |
|
|
2024
Q2 | $154M | Buy |
10,617,062
+835,590
| +9% | +$11.5M | 7.18% | 4 |
|
|
2024
Q1 | $163M | Hold |
9,781,472
| – | – | 6.86% | 4 |
|
|
2023
Q4 | $157M | Hold |
9,781,472
| – | – | 8.39% | 2 |
|
|
2023
Q3 | $132M | Hold |
9,781,472
| – | – | 8.74% | 2 |
|
|
2023
Q2 | $168M | Hold |
9,781,472
| – | – | 10.04% | 1 |
|
|
2023
Q1 | $162M | Buy |
9,781,472
+23,113
| +0.2% | +$370K | 11.71% | 1 |
|
|
2022
Q4 | $163M | Hold |
9,758,359
| – | – | 10.15% | 1 |
|
|
2022
Q3 | $167M | Buy |
9,758,359
+472,677
| +5% | +$6.87M | 12.84% | 1 |
|
|
2022
Q2 | $101M | Buy |
+9,285,682
| New | +$110M | 9.58% | 2 |
|
Frazier Life Sciences Management's HLVX Position: Q3 2025 in Review
Frazier Life Sciences Management sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 10,617,062 shares — an estimated $21.1M sold.
Frazier Life Sciences Management first reported a position in HLVX in Q2 2022 and held it in 13 quarters. The position peaked at $168M in Q2 2023. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.
- Frazier Life Sciences Management reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
- Frazier Life Sciences Management sold 10,617,062 HilleVax shares in Q3 2025, an estimated $21.1M.
- Frazier Life Sciences Management first reported a position in HilleVax in Q2 2022 and held it in 13 quarters.
- Frazier Life Sciences Management's HilleVax position peaked at $168M in Q2 2023.
- 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.
Based on Frazier Life Sciences Management's 13F filing for Q3 2025, filed 14 Nov 2025.